Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04070768
Title Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin + Venetoclax

Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.